KCM
TPTX

Kennedy Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Kennedy Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-110,748
Closed -$8.33M – 642
2022
Q2 		$8.33M Buy
110,748
+8,106
+8% +$360K 0.23% 141
2022
Q1 		$2.76M Buy
102,642
+80,944
+373% +$2.72M 0.07% 402
2021
Q4 		$1.03M Buy
21,698
+4,487
+26% +$201K 0.02% 514
2021
Q3 		$1.14M Buy
17,211
+1,939
+13% +$138K 0.03% 512
2021
Q2 		$1.19M Sell
15,272
-658
-4% -$48.6K 0.03% 513
2021
Q1 		$1.51M Sell
15,930
-1,525
-9% -$181K 0.03% 528
2020
Q4 		$2.13M Sell
17,455
-174
-1% -$19.1K 0.05% 500
2020
Q3 		$1.54M Sell
17,629
-139
-0.8% -$9.68K 0.04% 510
2020
Q2 		$1.15M Buy
17,768
+122
+0.7% +$7.04K 0.03% 565
2020
Q1 		$788K Buy
17,646
+2,362
+15% +$125K 0.03% 579
2019
Q4 		$952K Sell
15,284
-138
-0.9% -$6.57K 0.02% 617
2019
Q3 		$580K Buy
+15,422
New +$671K 0.01% 625

Kennedy Capital Management's TPTX Position: Q3 2022 in Review

Kennedy Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 110,748 shares — an estimated $8.33M sold.

Kennedy Capital Management first reported a position in TPTX in Q3 2019 and held it in 12 quarters. The position peaked at $8.33M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Kennedy Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 110,748 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8.33M.
  • Kennedy Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 12 quarters.
  • Kennedy Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $8.33M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Kennedy Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.